BIEL’s Multi‑Stream Royalty Revenue Model
Below are the four revenue streams BIEL could realistically monetize, plus the clinical multiplier from the phantom‑limb‑pain study.
1️⃣ ActiPatch — Consumer Retail (Electrome‑Driven)
Where it sells:
Pharmacies
Online retail
Consumer wellness channels
Partner likely involved - Electrome
Royalty structure
Retail price ≈ $39.99
Net revenue to Electrome ≈ $20
Royalty to BIEL ≈ $2 per unit (10%)
Volume potential
250,000–1,000,000 units annually
Annual revenue to BIEL
$500,000 – $2,000,000
2️⃣ RecoveryRx — Clinical / Post‑Surgical (VLMS‑Driven)
Where it sells:
Hospitals
Surgical centers
Orthopedic practices
Pain clinics
Partner likely involved - VLMS Global Healthcare (Keith Nalepka)
Royalty structure
Clinical device price ≈ $80–$120
Net revenue ≈ $60
Royalty to BIEL ≈ $5–$7 per unit
Volume potential
50,000–200,000 units annually
Annual revenue to BIEL
$300,000 – $1,400,000
3️⃣ RecoveryRx Veterinary — High‑Margin Niche
Where it sells:
Veterinary surgical recovery
Equine medicine
Companion‑animal pain management
Partner likely involved - VLMS or a dedicated veterinary distributor
Royalty structure
Veterinary device price ≈ $60–$100
Net revenue ≈ $50
Royalty to BIEL ≈ $5–$7.50 per unit
Volume potential
20,000–100,000 units annually
Annual revenue to BIEL
$100,000 – $750,000
4️⃣ Vagus Nerve Stimulation Device — Patent Pending
Where it fits:
Anxiety
Depression
PTSD
Inflammatory disorders
Autonomic dysfunction
Partner likely involved - Could be Electrome (consumer wellness) or VLMS (clinical) or Could attract a new neuromodulation partner
Royalty structure
Medical‑grade device: $150–$300 retail
Net revenue ≈ $120
Royalty to BIEL ≈ $10–$15 per unit
Volume potential
50,000–500,000 units annually
Highly dependent on regulatory path
Annual revenue to BIEL
$500,000 – $5,000,000
5️⃣ Phantom Limb Pain Study — Clinical Validation Multiplie
What it does:
Strengthens RecoveryRx’s clinical credibility
Opens VA and military channels
Supports insurance reimbursement
Increases hospital adoption
Justifies higher pricing
Revenue impact
Could add $300,000+ annually to RecoveryRx royalties
Could accelerate global clinical uptake
Could support reimbursement codes
This is a value amplifier, not a standalone product.
Combined Realistic Annual Revenue for BIEL
Realistic mid‑range scenario
ActiPatch: $800,000
RecoveryRx: $600,000
Veterinary: $240,000
Vagus nerve: $1,200,000
Phantom limb multiplier: $300,000
Total realistic annual revenue:
$3.1M – $4M
Best‑Case Annual Revenue (If Vagus Nerve + Phantom Limb Hit Big)
High‑success scenario
ActiPatch retail success
RecoveryRx hospital adoption
Veterinary expansion
Vagus nerve device becomes a wellness hit
Phantom limb study drives reimbursement
Total best‑case annual revenue:
$6M – $10M+
Why This Model Finally Works
Sree Koneru (Viant)
Enables scalable, FDA‑grade manufacturing
Reduces cost of goods
Supports large retail orders
Keith Nalepka (VLMS Global Healthcare)
Opens global clinical and hospital channels
Drives international adoption
Adds veterinary and specialty markets
Electrome
Drives consumer retail rollout
Invests in packaging, branding, and displays
BIEL
Provides the patents, technology, and IP backbone
For the first time, BIEL has the ecosystem to become a pure‑IP royalty company with multiple revenue streams instead of a single struggling product.
Below are the four revenue streams BIEL could realistically monetize, plus the clinical multiplier from the phantom‑limb‑pain study.
1️⃣ ActiPatch — Consumer Retail (Electrome‑Driven)
Where it sells:
Pharmacies
Online retail
Consumer wellness channels
Partner likely involved - Electrome
Royalty structure
Retail price ≈ $39.99
Net revenue to Electrome ≈ $20
Royalty to BIEL ≈ $2 per unit (10%)
Volume potential
250,000–1,000,000 units annually
Annual revenue to BIEL
$500,000 – $2,000,000
2️⃣ RecoveryRx — Clinical / Post‑Surgical (VLMS‑Driven)
Where it sells:
Hospitals
Surgical centers
Orthopedic practices
Pain clinics
Partner likely involved - VLMS Global Healthcare (Keith Nalepka)
Royalty structure
Clinical device price ≈ $80–$120
Net revenue ≈ $60
Royalty to BIEL ≈ $5–$7 per unit
Volume potential
50,000–200,000 units annually
Annual revenue to BIEL
$300,000 – $1,400,000
3️⃣ RecoveryRx Veterinary — High‑Margin Niche
Where it sells:
Veterinary surgical recovery
Equine medicine
Companion‑animal pain management
Partner likely involved - VLMS or a dedicated veterinary distributor
Royalty structure
Veterinary device price ≈ $60–$100
Net revenue ≈ $50
Royalty to BIEL ≈ $5–$7.50 per unit
Volume potential
20,000–100,000 units annually
Annual revenue to BIEL
$100,000 – $750,000
4️⃣ Vagus Nerve Stimulation Device — Patent Pending
Where it fits:
Anxiety
Depression
PTSD
Inflammatory disorders
Autonomic dysfunction
Partner likely involved - Could be Electrome (consumer wellness) or VLMS (clinical) or Could attract a new neuromodulation partner
Royalty structure
Medical‑grade device: $150–$300 retail
Net revenue ≈ $120
Royalty to BIEL ≈ $10–$15 per unit
Volume potential
50,000–500,000 units annually
Highly dependent on regulatory path
Annual revenue to BIEL
$500,000 – $5,000,000
5️⃣ Phantom Limb Pain Study — Clinical Validation Multiplie
What it does:
Strengthens RecoveryRx’s clinical credibility
Opens VA and military channels
Supports insurance reimbursement
Increases hospital adoption
Justifies higher pricing
Revenue impact
Could add $300,000+ annually to RecoveryRx royalties
Could accelerate global clinical uptake
Could support reimbursement codes
This is a value amplifier, not a standalone product.
Combined Realistic Annual Revenue for BIEL
Realistic mid‑range scenario
ActiPatch: $800,000
RecoveryRx: $600,000
Veterinary: $240,000
Vagus nerve: $1,200,000
Phantom limb multiplier: $300,000
Total realistic annual revenue:
$3.1M – $4M
Best‑Case Annual Revenue (If Vagus Nerve + Phantom Limb Hit Big)
High‑success scenario
ActiPatch retail success
RecoveryRx hospital adoption
Veterinary expansion
Vagus nerve device becomes a wellness hit
Phantom limb study drives reimbursement
Total best‑case annual revenue:
$6M – $10M+
Why This Model Finally Works
Sree Koneru (Viant)
Enables scalable, FDA‑grade manufacturing
Reduces cost of goods
Supports large retail orders
Keith Nalepka (VLMS Global Healthcare)
Opens global clinical and hospital channels
Drives international adoption
Adds veterinary and specialty markets
Electrome
Drives consumer retail rollout
Invests in packaging, branding, and displays
BIEL
Provides the patents, technology, and IP backbone
For the first time, BIEL has the ecosystem to become a pure‑IP royalty company with multiple revenue streams instead of a single struggling product.
1
